博暉創新(300318.SZ)子公司與君正集團簽訂769萬元購銷合同
格隆匯2月2日丨博暉創新(300318.SZ)公佈,為支援醫務人員抗擊新型冠狀病毒疫情,公司控股子公司廣東衞倫生物製藥有限公司(“廣東衞倫”)、河北大安製藥有限公司(“河北大安”)分別與內蒙古君正能源化工集團股份有限公司(“內蒙君正集團”)簽訂產品《購銷合同》。內蒙君正集團向廣東衞倫、河北大安採購合計金額為769萬元的凍幹靜注人免疫球蛋白和人免疫球蛋白產品,用於公益捐贈。公司與內蒙君正集團為同一實際控制人控制的公司,因此此次交易構成關聯交易。
此次關聯交易主要為支援醫務人員抗擊新型冠狀病毒疫情。不存在損害公司及其他中小股東利益的情況,也不存在違反相關法律法規的情況。此次關聯交易事項不會對公司的財務狀況、經營成果及獨立性構成重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.